EATG » Janssen presents new data for SYMTUZA

Janssen presents new data for SYMTUZA

Janssen presents new data from first Phase 3 trial of a single-tablet regimen in a rapid initiation model of care demonstrating safety and efficacy with SYMTUZA® through 48 weeks

— High proportion of patients achieve undetectable viral loads after rapidly starting SYMTUZA®

Read the full press release here.


 

Source:
Janssen
News categories: HIV treatment